XOLAIR Injection Treatment Across the Southeast
XOLAIR injection treatment is given under the skin, not through an IV. XOLAIR (omalizumab) is a prescription biologic administered by subcutaneous injection.
Eligible patients with a specialist’s order may receive monitored outpatient treatment through TwelveStone’s network of 30+ centers across Alabama, Georgia, Indiana, Kentucky, Mississippi, South Carolina, Tennessee, and Virginia. The care team coordinates with the prescriber, helps verify benefits, and identifies an appropriate treatment location before care begins.
What XOLAIR Is Used For
Omalizumab is the generic name for XOLAIR. It is an anti-IgE biologic that binds to immunoglobulin E (IgE), an antibody involved in allergic responses.
A qualified specialist determines whether XOLAIR is appropriate based on your diagnosis, medical history, previous treatment, and the medication’s approved use. TwelveStone administers prescribed treatment but does not determine which medication you should receive.
XOLAIR has FDA-approved uses for several allergic and inflammatory conditions. Eligibility differs by diagnosis, age, prior treatment response, and other clinical factors:
| Condition | How XOLAIR may be used |
|---|---|
| Allergic asthma | For patients age 6 and older with moderate-to-severe persistent allergic asthma that meets specific allergy-testing and treatment-response criteria. |
| Chronic rhinosinusitis with nasal polyps (CRSwNP) | As add-on maintenance treatment for adults age 18 and older whose symptoms have not responded adequately to nasal corticosteroids. |
| IgE-mediated food allergy | For patients age 1 and older to help reduce allergic reactions that may occur after accidental exposure. Food-allergen avoidance must continue. |
| Chronic spontaneous urticaria (CSU) | For adults and adolescents age 12 and older who remain symptomatic despite H1 antihistamine treatment. |
XOLAIR is not a rescue medication. It does not treat sudden asthma symptoms or an emergency allergic reaction, including anaphylaxis. Continue following the emergency treatment plan, rescue medications, and allergen-avoidance instructions provided by your healthcare team.
Who May Be Eligible for XOLAIR?
Eligibility for XOLAIR depends on the condition being treated, age, medical history, previous treatment response, and the medication’s labeled criteria. A qualified prescriber reviews these factors and determines whether XOLAIR is appropriate for you.
For conditions such as allergic asthma, chronic spontaneous urticaria, or chronic rhinosinusitis with nasal polyps, the prescriber reviews whether symptoms remain inadequately controlled despite the treatments relevant to that diagnosis. Because the eligibility criteria differ by condition, XOLAIR requires an individualized clinical evaluation.
For IgE-mediated food allergy, a specialist may prescribe XOLAIR to help reduce allergic reactions that can occur after accidental exposure. XOLAIR is used together with food-allergen avoidance and does not replace your emergency treatment plan.
Continue your current medications, avoidance measures, and emergency treatment plan unless your prescriber tells you otherwise. Once XOLAIR is prescribed, TwelveStone coordinates treatment with the referring team. Referring clinicians can find enrollment and care-coordination information on TwelveStone’s provider page.
How XOLAIR Dosing and Injection Frequency Are Determined
There is no single XOLAIR dose or injection schedule for every patient. For allergic asthma, chronic rhinosinusitis with nasal polyps, and IgE-mediated food allergy, the prescribing specialist uses pretreatment total IgE and body weight to determine the ordered dose and whether treatment is scheduled every two or four weeks.
Chronic spontaneous urticaria is different. Its dosing is not based on serum IgE level or body weight and is generally scheduled every four weeks according to the prescriber’s order. Depending on the prescribed dose and product presentation, a treatment visit may include more than one subcutaneous injection.
Follow the prescribed dose and schedule exactly. Do not change your treatment timing or restart XOLAIR after a missed dose or treatment gap without guidance from your prescriber. TwelveStone’s care team confirms the order and coordinates administration in an outpatient setting. Learn more about TwelveStone infusion treatments and outpatient treatment support.
What to Expect at Your XOLAIR Injection Appointment
Your visit is an outpatient injection appointment, not an IV infusion session. At a TwelveStone outpatient center, trained clinical staff administer prescribed IV and subcutaneous therapies in a monitored setting, including medications that require post-treatment observation.
Your appointment generally follows a straightforward clinical sequence:
XOLAIR carries a boxed warning for anaphylaxis, a potentially life-threatening allergic reaction. Anaphylaxis can occur after the first dose or later in treatment, which is why XOLAIR therapy is initiated in a healthcare setting and patients are monitored according to the prescribed safety plan.
Tell the care team immediately if you develop trouble breathing, throat or facial swelling, faintness, widespread hives, or other signs of a severe allergic reaction. If symptoms develop after you leave the treatment setting, follow your emergency plan and seek immediate medical care when appropriate.
When XOLAIR May Be Self-Administered at Home
Some patients may eventually be eligible to self-administer XOLAIR at home, but a prefilled syringe or autoinjector does not automatically make home treatment appropriate.
Self-administration is considered only after treatment has been safely established under healthcare-provider guidance and the prescriber evaluates allergic-reaction risk, training needs, and the patient’s ability to use the device correctly.
The prescribing information includes several factors for selecting patients for self-administration, including successful supervised treatment without hypersensitivity reactions and the ability to recognize anaphylaxis and use the injection device correctly. Because age, diagnosis, treatment history, and individual risk all matter, the final decision remains with the prescribing healthcare provider.
Home administration requires proper refrigerated storage, careful handling, and safe disposal of used needles or devices. Patients and caregivers also need a clear plan for recognizing and responding to allergic reactions. Always follow the specific Instructions for Use provided with your prescribed XOLAIR device, including preparation, injection, storage, and disposal instructions.
Continue receiving XOLAIR in the prescribed setting and on the prescribed schedule unless your healthcare provider changes the plan. If you miss an appointment, miss a dose, or experience a meaningful change in symptoms, contact your care team for guidance on the next step.
Coordinating Your Outpatient XOLAIR Care
Once a qualified clinician prescribes XOLAIR, TwelveStone helps coordinate the next steps toward an outpatient injection appointment. The care team works with the prescriber’s office to verify benefits, support prior-authorization or payer-documentation requirements when applicable, coordinate scheduling, and keep the referring provider connected to the treatment plan.
Insurance coverage and out-of-pocket responsibility vary by health plan, specialty-pharmacy requirements, prior-authorization criteria, and available assistance programs. Coverage cannot be confirmed until the order and insurance benefits are reviewed, but TwelveStone’s coordination team can explain required documentation, verify applicable benefits, and help identify financial-assistance resources when available.
TwelveStone provides community-based treatment in private outpatient settings supported by experienced infusion clinicians and PharmD professionals. Its network includes 30+ centers across Alabama, Georgia, Indiana, Kentucky, Mississippi, South Carolina, Tennessee, and Virginia, helping eligible patients receive coordinated care closer to home when an appropriate location is available.
